Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Risico op psoriasis na behandeling met een TNF-α-remmer
jul 2022 | IBD, Psoriasis, RA